AI Drug discovery at your fingertips
LaunchPad
The "Factory-level platform" operates 24/7 for uninterrupted production with the goal of "candidate materials in target or disease" through rapid and standardized operating processes. Using DeepMatcher®-based in-silico methods, candidate substances are derived for over 100 targets closely associated with major diseases such as autoimmune, neurological, hematological, solid tumor, and cardiovascular disorders. These candidate materials, after undergoing rigorous validation through in-vitro/in-vivo assays by global CRO, are finally produced as ”first in class and best in class” materials. The Materials produced through the Factory-level are built into an inventory and provided through our LaunchPad service. The LaunchPad service minimizes the risk associated with customer drug development while meeting high medical demand by offering pre-validated drug candidate materials with high success rates and commercial viability. It provides customers with a mutually beneficial strategic service.
STB LaunchPad Covers Major Indications
STB LaunchPad includes many well-known targets in autoimmune, cancer, CNS, metabolic and rare diseases, where the unmet need in the market remains. In the interest in progress for patients and their families, STB LaunchPad is de-risking these targets and compounds are ready for partners to bring to the IND and clinical phases.
Cancer
Cancer is caused when cells in the body grow in a way that is uncontrolled and not normal, killing normal cells and often causing death. (91 targets)
Autoimmune Disease
Autoimmune disease happens when the body's natural defense system can't tell the difference between your own cells and foreign cells, causing the body to mistakenly attack normal cells. (17 targets)
CNS
CNS diseases include a broad spectrum of disorders in which brain or spinal cord function is diminished or impaired, resulting in diminished motor, sensory, or cognitive performance. (20 targets)
Others
This categories is included the targets which is metabolic disease, inflammatory diseases and rare diseases. (11 targets)
Our Service
To accelerate drug development by continuously searching and developing drug candidates, independent of indication. Our platform is disease-agnostic and facilitates discovering first-in-class and best-in-class compounds rapidly.
Drug candidates for different indications are continuously released
What We Offer
Syntekabio (STB) has developed a collection of AI-discovered hit and lead compounds for well-known drug targets across major therapeutic indications via our STB LaunchPad program.
This R&D project leverages our in-silico AI technology, DeepMatcher®, to develop many, concurrent drug pipelines simultaneously. We have initiated hit- and lead- discovery on over 100 priority protein targets, related to 60-70% of major disease indications, supporting our goal of making many, novel molecules available to our partners rapidly and at scale.
LaunchPad
To date, our collection of candidates includes validated hits and leads, as well as compounds already in animal-stage testing. The list is inclusive of both Best-in-class and First-in-class candidates, based on the target's broader clinical development stage. The newly discovered STB LaunchPad compounds are available to biotechnology and pharmaceutical companies, interested in partnering with us to accelerate their drug discovery and preclinical phase pipelines.
Expo-ro 1, Expo Tower #1903,
Yuseong-gu, Daejeon,
Republic of Korea
Headquarter
Samunan-ro 92, Gwanghwamun Officia Building #1708,
Jongno-gu, Seoul, Republic of Korea
Business Center
425 Fifth Avenue Suite 505 New York,
NY, USA #10016
Syntekabio USA Inc.
© 2024 Syntekabio, Inc. All rights reserved.
